#USA #New York #Class Action #Gross Law Firm #Unicycive Therapeutics

Unicycive Therapeutics Class Action Alert

On September 29, 2025, the Gross Law Firm announced the initiation of a securities class action targeting shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY). This action is directed toward investors who acquired shares during a specific period concerning allegations of misleading information regarding the company’s product development and regulatory compliance.

Important Dates and Details

Shareholders are strongly encouraged to contact the Gross Law Firm if they purchased shares between March 29, 2024, and June 27, 2025. This class action aims to identify a lead plaintiff to represent the interests of affected shareholders. However, it's crucial to note that being appointed as lead plaintiff is not a prerequisite for recovery.

Allegations

The core allegations of the class action include that Unicycive's management provided materially false and misleading statements. Specifically, it was claimed that:
1. The company overstated its preparedness to meet the FDA's manufacturing compliance standards.
2. The regulatory prospects related to the oxylanthanum carbonate new drug application were also exaggerated.
3. As a consequence, the public statements made by the defendants throughout this period were misleading.

Registration Deadline

Interested shareholders should promptly register their information for this class action by visiting the designated link to ensure they receive appropriate updates during the case's progression. The deadline for potential lead plaintiffs is set for October 14, 2025.

How to Participate

Once shareholders register, they will gain access to a portfolio monitoring service designed to keep them informed of the ongoing legal proceedings. Participation in this class action involves no cost or obligation, enabling investors to potentially secure compensation for any losses incurred due to the alleged misconduct.

About the Gross Law Firm

Renowned for its commitment to protecting investors' rights, the Gross Law Firm stands as a well-respected class action law firm. The firm focuses on recovering losses stemming from deceit, fraud, or unethical business practices, ensuring companies are held accountable for misleading investors through false statements or omissions of critical information that inflate stock prices illicitly.

Contact Information

Investors with queries or those looking to participate can reach out to the Gross Law Firm at their New York office:

• - Address: 15 West 38th Street, 12th Floor, New York, NY 10018
• - Phone: (646) 453-8903
• - Email: [email protected]

The Gross Law Firm emphasizes the importance of corporate accountability and aims to assist investors who have encountered losses due to questionable business practices. Participation in this class action represents a united front for shareholders affected by the actions of Unicycive Therapeutics' management during the stated period.

This class action serves as a critical opportunity for investors to seek redress and ensure that companies adhere to responsible and transparent business practices moving forward. Stay informed and don’t miss your chance to register by the approaching deadline.